On March 27, 2026, Enveric Biosciences, Inc. (NASDAQ: ENVB) announced its financial results for the fourth quarter and the fiscal year ended December 31, 2025. The company reported a net loss of $4.0 million for the fourth quarter, which included $0.3 million in net non-cash expenses, translating to a basic and diluted loss per share of $6.12. This compares to a net loss of $3.2 million for the same quarter in 2024, which had a basic and diluted loss per share of $58.06. Despite the losses, Enveric highlighted significant advancements in its product development, particularly with its lead drug candidate, EB-003, which showed promising preclinical results in treating severe chronic depression and PTSD. The company is preparing for an IND application to the FDA, marking a critical milestone in its development pipeline. Enveric also announced the withdrawal of a Post-Grant Review petition against its patent, reinforcing its intellectual property position. The company raised a total of $12.2 million in gross proceeds during the fiscal year 2025, indicating a strong financial backing for its ongoing projects. Enveric's strategic focus on developing non-hallucinogenic neuroplastogenic therapeutics positions it well within the growing mental health treatment market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.